Keval Patel, MD
Cardiovascular Disease · Medford, ORNPI 1457649626
Payments from drug & device makers
Across 32 payments — averaging $62.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$170
- Abbott$168
- Boston Scientific$44
- Cardinal Health 200 LLC$28
- Mylan Pharmaceuticals Inc.$23
- plus $29 from 2 others
What the payments were for
- Travel & lodging$1,12256%
- Food & beverage$86343%
- Education$111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 10 | $1,534 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $170 |
| Abbott | 3 | $168 |
| Boston Scientific | 2 | $44 |
| Cardinal Health 200 LLC | 2 | $28 |
| Mylan Pharmaceuticals Inc. | 1 | $23 |
| Penumbra, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reveal LINQ$1,368
How this compares
$1,996 in reported general payments places this provider in the 55th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 462 | $541,442 |
| XareltoRivaroxaban | 149 | $189,037 |
| EntrestoSacubitril/Valsartan | 95 | $139,913 |
| JardianceEmpagliflozin | 80 | $108,334 |
| FarxigaDapagliflozin Propanediol | 51 | $48,143 |
| Repatha SureclickEvolocumab | 36 | $27,398 |
| BrilintaTicagrelor | 18 | $18,503 |
| Metoprolol Succinate | 781 | $14,880 |
| Praluent PenAlirocumab | 15 | $14,448 |
| Rosuvastatin Calcium | 542 | $8,568 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $7,092 |
| Flecainide Acetate | 131 | $6,177 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 177 | $5,615 |
| Ranolazine ErRanolazine | 39 | $3,637 |
| Atorvastatin Calcium | 303 | $3,495 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Medford
- Mark HuthMedford$38K
- Firas ZahrPortland$7.7M
- Ahmad MasriPortland$2.6M
- Scott ChadderdonPortland$1.6M
- Tyler GluckmanPortland$755K
- Stephen HeitnerPortland$434K
- Kathy GreweHood River$376K
- Matthew TrojanSpringfield$255K
- Maros FerencikPortland$239K
- Ian RiddockBend$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.